Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Mihoko Sutoh-Yoneyama"'
Autor:
Tohru Yoneyama, Shingo Hatakeyama, Mihoko Sutoh-Yoneyama, Taku Yoshiya, Tsuyoshi Uemura, Takehiro Ishizu, Minoru Suzuki, Shingo Hachinohe, Shintaro Ishiyama, Motohiro Nonaka, Michiko N. Fukuda, Chikara Ohyama
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-15 (2021)
Abstract Background p-Boronophenylalanine (10BPA) is a powerful 10B drug used in current clinical trials of BNCT. For BNCT to be successful, a high (500 mg/kg) dose of 10BPA must be administered over a few hours. Here, we report BNCT efficacy after r
Externí odkaz:
https://doaj.org/article/a8a6401007f9447bab9c5194fe2dff25
Autor:
Mihoko Sutoh Yoneyama, Tohru Yoneyama, Yuki Tobisawa, Hayato Yamamoto, Shingo Hatakeyama, Takahiro Yoneyama, Yasuhiro Hashimoto, Tadashi Suzuki, Chikara Ohyama
Publikováno v:
Biochemical and Biophysical Research Communications. 613:1-6
Cell surface hyaluronidase transmembrane protein 2 (TMEM2), which also serves as a reportedly functions in malignancy of several solid tumors. However, TMEM2 involvement in bladder cancer (BCa) is unknown. Therefore, we investigate potential changes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ead27763a3cfc07b7053b7a94ba1569c
https://doi.org/10.1016/j.bbrc.2022.04.118
https://doi.org/10.1016/j.bbrc.2022.04.118
Autor:
Kyo Togashi, Tohru Yoneyama, Mihoko Sutoh Yoneyama, Hayato Yamamoto, Shingo Hatakeyama, Takahiro Yoneyama, Yasuhiro Hashimoto, Masayuki Futagami, Chikara Ohyama
Publikováno v:
IJU Case Reports. 5:186-190
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a8e745e76e1553f674a4743e9f501e68
https://doi.org/10.1002/iju5.12433
https://doi.org/10.1002/iju5.12433
Autor:
Fumiyasu Tsushima, Akihiro Ito, Yasuhiro Hashimoto, Shingo Kakeda, Hiroyuki Ito, Chikara Ohyama, Masaki Momota, Tohru Yoneyama, Shintaro Narita, Yuki Tobisawa, Shingo Hatakeyama, Mihoko Sutoh Yoneyama, Hayato Yamamoto, Jehonathan H. Pinthus, Norihiko Tsuchiya, Takuma Narita, Wilhelmina C.M. Duivenvoorden, Takahiro Yoneyama, Koji Mitsuzuka, Tomonori Habuchi, Hirotake Kodama
Publikováno v:
The Prostate. 81:1411-1427
Background The presence of glycosylated isoforms of prostate-specific antigen (PSA) in prostate cancer (PC) cells is a potential marker of their aggressiveness. We characterized the origin of α2,3-sialylated prostate-specific antigen (S23PSA) by tis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eefd90daa990c49e8d0b6277163ea941
https://doi.org/10.1002/pros.24239
https://doi.org/10.1002/pros.24239
Autor:
Mihoko Sutoh Yoneyama, Sakae Konishi, Takahiro Yoneyama, Chikara Ohyama, Shingo Hatakeyama, Teppei Okamoto, Itsuto Hamano, Yasuhiro Hashimoto, Yuka Kubota, Hayato Yamamoto, Tohru Yoneyama
Publikováno v:
World Journal of Urology. 39:3265-3271
To investigate the prognostic significance of total cell-free DNA (cfDNA) level and androgen receptor amplification (AR-amp) in patients with castration-resistant prostate cancer (CRPC). We retrospectively compared the total cfDNA level and AR-amp in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2d9094bb6ea5b77255c0d57569d4348
https://doi.org/10.1007/s00345-021-03649-x
https://doi.org/10.1007/s00345-021-03649-x
Autor:
Ishiyama Shintaro, Michiko N. Fukuda, Mihoko Sutoh Yoneyama, Chikara Ohyama, Takehiro Ishizu, Shingo Hachinohe, Tohru Yoneyama, Motohiro Nonaka, Tsuyoshi Uemura, Minoru Suzuki, Taku Yoshiya, Shingo Hatakeyama
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-5 (2021)
An amendment to this paper has been published and can be accessed via the original article.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::137bcfac5b1eae1e879e03a832ff6403
https://doaj.org/article/a1d6f3d092594bd5b59f80670477a420
https://doaj.org/article/a1d6f3d092594bd5b59f80670477a420
Autor:
Tohru Yoneyama, Shingo Hatakeyama, Mihoko Sutoh Yoneyama, Yuki Tobisawa, Takuma Narita, Hirotake Kodama, Masaki Momota, Hiroyuki Ito, Shintaro Narita, Fumiyasu Tsushima, Koji Mitsuzuka, Takahiro Yoneyama, Yasuhiro Hashimoto, Wilhelmina Duivenvoorden, Jehonathan H. Pinthus, Shingo Kakeda, Akihiro Ito, Norihiko Tsuchiya, Tomonori Habuchi, Chikara Ohyama
Publikováno v:
Journal of Urology. 207
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3706ff68085d18f7b2a57094035f680d
https://doi.org/10.1097/ju.0000000000002611.06
https://doi.org/10.1097/ju.0000000000002611.06
Autor:
Tohru Yoneyama, Shingo Hatakeyama, Mihoko Sutoh Yoneyama, Taku Yoshiya, Tsuyoshi Uemura, Takehiro Ishizu, Minoru Suzuki, Shingo Hachinohe, Shintaro Ishiyama, Motohiro Nonaka, Michiko N. Fukuda, Chikara Ohyama
Publikováno v:
Journal of Urology. 207
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e27c74e9e59d69bf3e0381f5860e3152
https://doi.org/10.1097/ju.0000000000002523.19
https://doi.org/10.1097/ju.0000000000002523.19
Autor:
Takuma Narita, Daisuke Noro, Sakae Konishi, Mihoko Sutoh Yoneyama, Chikara Ohyama, Kyo Togashi, Takahiro Yoneyama, Yuki Tobisawa, Teppei Okamoto, Tohru Yoneyama, Yasuhiro Hashimoto, Tendo Sato, Shingo Hatakeyama, Hayato Yamamoto
Publikováno v:
Scientific Reports
Scientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
Scientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
The evaluation of surgical damage is challenging because of the lack of specific biomarkers. Total cell-free DNA (cfDNA) levels have been reported to increase with external trauma and may be a biomarker for tissue damage. To investigate the utility o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ec12efd017ea7401cb47dfc81e97e4c
https://pubmed.ncbi.nlm.nih.gov/34764347
https://pubmed.ncbi.nlm.nih.gov/34764347
Autor:
Takatoshi Kaya, Kazuyuki Mori, Tohru Yoneyama, Yoshihiko Suda, Tomonori Kaneko, Jehonathan H. Pinthus, Yasuhiro Hashimoto, Yuki Tobisawa, Chikara Ohyama, Wilhelmina C.M. Duivenvoorden, Shingo Hatakeyama, Koji Mitsuzuka, Takuya Koie, Robert A. Gardiner, Teppei Okubo, Mihoko Sutoh Yoneyama, Akihiro Ito
Publikováno v:
Cancer Science
To reduce unnecessary prostate biopsies (Pbx), better discrimination is needed. To identify clinically significant prostate cancer (CSPC) we determined the performance of LacdiNAc‐glycosylated prostate‐specific antigen (LDN‐PSA) and LDN‐PSA n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b31de959a42ec21bc78e3f8b37441f8
https://doi.org/10.1111/cas.14082
https://doi.org/10.1111/cas.14082